Vivopower Intl (NASDAQ:VVPR) Stock, Quote.Headers.trade-ideas

Vivopower Intl

Vivopower International PLC is a solar power company. The company provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Critical Power Services segment which consists of the design, supply, installation, and maintenance of power and control systems. It provides its solutions to government, commercial, and industrial customers. Nearly all of the revenue derives from Australia.

Vivopower International

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

EFSH

GLMD

HCTI

IOBT

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

ADXN

ATXG

BLDP

CNET

CTNT

GLPG

GSX Techedu Inc. American Depositary Shares

GOTU

ILAG

MAPS

SMFL

SOPA

TANH

TCOM

TRIB

TUYA

Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Penny,Stock,Investments,Taking,Off,Concept

Intraday Update

AEHL

AEHR

ALAR

ANVS

CETU

DLPN

FENG

FUFU

GATO

IDYA

IONM

KRUS

KZIA

LGMK

LGVN

LNTH

LUCY

NAAS

NISN

QURE

RMCF

RXST

SDST

SEEL

SISI

SNGX

TCJH

TMDX

VRPX

VSEE

ZAPP

Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

VivoPower International PLC - Ordinary Shares

Vivopower International PLC

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

CNTX

HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $6 Price Target

Baird analyst Brian Skorney maintains Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Outperform and raises the price target from $58 to $60.

BHVN

Baird Maintains Outperform on Biohaven, Raises Price Target to $60

Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape.
A widely followed private sector survey by S&amp;P Global revealed that output growth slightly exceeded expectations in September, buoyed by stronger services activity. However, the report also signaled a reawakening of inflationary pressures, raising concerns about <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40965082/feds-historic-dissenter-bowman-says-smaller-interest-rate-cut-was-justified-we-have-no">future monetary policy moves.</a>
The latest betting-implied odds from Polymarket show Kamala Harris at 51% to win the 2024 U.S. presidential election, surpassing former President Donald Trump, who has seen his consensus slips in recent weeks.
Among major assets, gold continues its upward momentum, setting new all-time highs as investors flock to safe-haven assets amid global uncertainty.
Meanwhile, natural gas prices spiked over 4%, hitting a three-month high early Monday. The rise follows the formation of another storm in the Gulf of Mexico, which threatens to further disrupt supply chains already impacted by Hurricane Francine.
The geopolitical situation in the Middle East remains tense, with Israel targeting new Hezbollah sites in Lebanon and the U.S. sending additional military troops to the region amid rising conflict. 
Despite the turmoil, oil prices fell by 2%, suggesting that supply fears may be easing for the moment. 
In the cryptocurrency space, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased by 0.5%, showing little movement.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,816.41</td>
<td>0.1 %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,707.19</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,002.30</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.90</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">Benzinga Pro</a> data: 
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was flat at $568.42.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;edged 0.1% lower to $420.26.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) flattened at $482.36.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $220.36.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.6%. The Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.6%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rallied 4%, while General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 2.7% reacting to the latest export ban proposal from the U.S. administration <a href="https://www.benzinga.com/markets/asia/24/09/40981254/chinese-vehicle-tech-faces-biden-administration-ban-over-national-security-concerns-china-ev-stocks">on Chinese-made vehicles. </a></li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rose over 3% amid rumors that Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">exploring a potential takeove</a>r. Shares of Qualcomm fell 2%.</li>
<li>Ciena Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) obtained a double upgrade from Sell to Buy by Citigroup. </li>
<li>Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) fell over 6% amid negative weight-loss study data.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40965082/feds-historic-dissenter-bowman-says-smaller-interest-rate-cut-was-justified-we-have-no">Fed&#8217;s Historic Dissenter Bowman Says Smaller Interest Rate Cut Was Justified: &#8216;We Have Not Yet Achieved Our Inflation Goal&#8217;</a></li>
</ul>
This image was created using artificial intelligence MidJourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Global

ETFs

$BTC

CIEN

SPDR Dow Jones Industrial Average ETF Trust

INTC

QCOM

TSLA

VKTX

Select Sector SPDR-Consumer Discretionary

US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?

Investors in BRC Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 18, 2024 $1 Call had some of the highest implied volatility of all equity options today.
<h2>What is Implied Volatility?</h2>
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
<h2>What do the Analysts Think?</h2>
Clearly, options traders are pricing in a big move for BRC shares, but what is the fundamental picture for the company? Currently, BRC is a Zacks Rank #4 (Sell) in the Consumer Products - Staples industry that ranks in the Bottom 44% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from breakeven to a loss of 2 cents in that period.
Given the way analysts feel about BRC right now, this huge implied volatility could mean there&#39;s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
<a href="https://www.zacks.com/stock/news/2339965/is-the-options-market-predicting-a-spike-in-brc-brcc-stock?cid=CS-BENZ-FT-tale_of_the_tape|options-2339965">To read this article on Zacks.com click here.</a>

Earnings

Penny Stocks

Options

Small Cap

BRCC

Is the Options Market Predicting a Spike in BRC Stock?

HC Wainwright &amp; Co. analyst Yi Chen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and raises the price target from $19 to $22.

BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $22

Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 32 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 56% bearish. Among these notable options, 19 are puts, totaling $1,013,010, and 13 are calls, amounting to $1,746,486.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $65.0 for CVS Health, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $45.0 to $65.0, over the past month.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727111767_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$2.16</td>
<td>$1.91</td>
<td>$1.89</td>
<td>$58.00</td>
<td>$739.1K</td>
<td>42</td>
<td>3.8K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.78</td>
<td>$55.00</td>
<td>$410.3K</td>
<td>3.2K</td>
<td>710</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.45</td>
<td>$1.44</td>
<td>$1.45</td>
<td>$57.00</td>
<td>$149.4K</td>
<td>0</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$60.00</td>
<td>$107.1K</td>
<td>6.3K</td>
<td>676</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$60.00</td>
<td>$99.7K</td>
<td>6.3K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of CVS Health</h3>
<ul>
<li>Currently trading with a volume of 2,906,387, the CVS's price is up by 0.51%, now at $57.8. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $64.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $68. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on CVS Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Colgate-Palmolive. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 2 are puts, totaling $61,200, and 6 are calls, amounting to $228,304.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $105.0 for Colgate-Palmolive, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Colgate-Palmolive options trades today is 881.17 with a total volume of 1,167.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Colgate-Palmolive's big money trades within a strike price range of $95.0 to $105.0 over the last 30 days.
<h3>Colgate-Palmolive Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727111761_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.5</td>
<td>$97.50</td>
<td>$55.2K</td>
<td>520</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$105.00</td>
<td>$48.0K</td>
<td>2.6K</td>
<td style="text-align: right;">530</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.5</td>
<td>$7.2</td>
<td>$7.48</td>
<td>$97.50</td>
<td>$37.4K</td>
<td>612</td>
<td style="text-align: right;">92</td>
</tr>
<tr>
<td>CL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$95.00</td>
<td>$34.2K</td>
<td>250</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$30.8K</td>
<td>195</td>
<td style="text-align: right;">192</td>
</tr>
</tbody>
</table>

<h3>About Colgate-Palmolive</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
In light of the recent options history for Colgate-Palmolive, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Colgate-Palmolive</h3>
<ul>
<li>Trading volume stands at 1,380,483, with CL's price up by 0.51%, positioned at $103.59.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 32 days.</li>
</ul>
<h3>Expert Opinions on Colgate-Palmolive</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $110.33333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has revised its rating downward to Underweight, adjusting the price target to $100. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Colgate-Palmolive, which currently sits at a price target of $122. 
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Hold, adjusting the price target to $109. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Colgate-Palmolive, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Colgate-Palmolive

High-rolling investors have positioned themselves bullish on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TXN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Texas Instruments. This is not a typical pattern.
The sentiment among these major traders is split, with 63% bullish and 27% bearish. Among all the options we identified, there was one put, amounting to $39,510, and 10 calls, totaling $512,951.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $190.0 and $210.0 for Texas Instruments, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Texas Instruments's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Texas Instruments's whale activity within a strike price range from $190.0 to $210.0 in the last 30 days. 
<h3>Texas Instruments Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727111756_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.25</td>
<td>$16.2</td>
<td>$16.25</td>
<td>$200.00</td>
<td>$156.0K</td>
<td>3.2K</td>
<td style="text-align: right;">349</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.85</td>
<td>$15.65</td>
<td>$15.85</td>
<td>$200.00</td>
<td>$76.1K</td>
<td>3.2K</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.1</td>
<td>$8.6</td>
<td>$8.7</td>
<td>$210.00</td>
<td>$42.6K</td>
<td>1.5K</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>TXN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$4.05</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$205.00</td>
<td>$39.5K</td>
<td>13</td>
<td style="text-align: right;">201</td>
</tr>
<tr>
<td>TXN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.65</td>
<td>$6.5</td>
<td>$6.55</td>
<td>$210.00</td>
<td>$39.3K</td>
<td>1.4K</td>
<td style="text-align: right;">106</td>
</tr>
</tbody>
</table>

<h3>About Texas Instruments</h3>
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Following our analysis of the options activities associated with Texas Instruments, we pivot to a closer look at the company's own performance.
<h3>Texas Instruments's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,143,121, with TXN's price up by 0.23%, positioned at $203.77.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Texas Instruments, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Texas Instruments

KB Home (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kbh#NYSE">KBH</a>) is slated to report third-quarter fiscal 2024 results (ended Aug. 31) on Sept. 24, after the closing bell.
In the last reported quarter, KB Home&#39;s earnings and revenues beat the Zacks Consensus Estimate by 20.8% and 4.3%, respectively. On a year-over-year basis, earnings increased 11% on 3.4% lower revenues.
The company&#39;s earnings topped analysts&#39; expectations in 31 of the trailing 34 quarters.
<div class="chart_embed">
<h3>KB Home Price and EPS Surprise</h3>
<img alt="KB Home Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9d/1727092560.png" style="height:263px; width:538px" title="" />
KB Home price-eps-surprise | KB Home Quote
</div>
<h2>How Are Estimates Placed for KBH?</h2>
For the quarter to be reported, the Zacks Consensus Estimate for earnings has remained unchanged at $2.04 per share over the past 60 days. The projected figure indicates an increase of 13.3% from the year-ago quarter&#39;s earnings of $1.80 per share.
The consensus estimate for revenues is pegged at $1.73 billion, implying growth of 8.8% from the prior-year quarter.
<h2>What the Zacks Model Unveils for KB Home</h2>
Our proven model predicts an earnings beat for KB Home this time around. This is because a stock needs to have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: KB Home has an Earnings ESP of +0.08%.
Zacks Rank: KB Home currently has a Zacks Rank #3.
<h2>Factors to Shape KBH&#39;s Q3 Results</h2>
Revenues: KB Home&#39;s top line in third-quarter fiscal 2024 is likely to have increased, given higher Housing revenues primarily attributable to growth in deliveries and favorable pricing. The company has been benefiting from the strong buyer demand, particularly for built-to-order homes, despite the volatility in mortgage rates.
The company&#39;s focus on personalization and its ability to offer both quick move-in and personalized homes might have helped the company drive growth. KB Home has also been utilizing mortgage buydowns as a key component of its strategy to maintain strong sales amid fluctuating mortgage rates.
Although the company has not provided an explicit forecast for its third-quarter absorption pace, the positive momentum from the fiscal second quarter &mdash; driven by strong demand, shorter build times, and strategic pricing &mdash; suggests that the absorption pace is expected to remain solid in the fiscal third quarter. The company is focusing on balancing pace and pricing to optimize margins while still driving volume.
The company expects housing revenues in the range of $1.65-$1.75 billion compared with the year-ago figure of $1.57 billion. KBH anticipates the average selling price&nbsp;to be $482,000, indicating an increase from $466,300 reported a year ago.
Our model projects housing revenues to grow 9.1% year over year to $1.72 billion in the quarter. We expect ASP to increase 3.3% to $481,500. We expect total deliveries in the quartet to grow 5.6% year over year.
Margins: Although initiatives like the Returns-Focused Growth Plan and Built-to-Order approach are positives, increasing construction and labor costs are likely to put pressure on the bottom line.
The company anticipates that the housing gross margin for the third quarter of 2024 will decline between 21% and 21.4% (compared with 21.5% in the year-ago quarter). This projection accounts for the concessions provided to homebuyers in the latter half of last year, which were influenced by the challenging market conditions at that time and is expected to close in this quarter.
Selling, general &amp; administrative expenses (SG&amp;A), as a percentage of housing revenues, are likely to be 9.9%-10.3%. We expect SG&amp;A expenses to be 10.2% in the quarter, the same as the year-ago figure.
The company expects adjusted operating margin between 10.8% and 11.4%. Our model predicts the adjusted operating margin to be 10.9% in the quarter, down from 11.4% a year ago.
The company expects an effective tax rate of approximately 24% for the quarter.
Orders &amp; Backlogs: We anticipate that new orders will increase to 3,357 units, up 8.4% from the previous year. With a limited supply of pre-owned homes available, homebuyers are turning their attention to builders who have increased their construction efforts to meet the rising demand. KB Home, along with other homebuilding companies, has benefited significantly from this trend despite ongoing challenges.
We expect the backlog to be 6,062 units, implying a decline from 7,008 units reported in the prior-year quarter.
Meanwhile, our model predicts Financial Services revenues to be $8.3 million for the fiscal third quarter. We expect Financial Services pretax income to be $12.2 million in the quarter compared with the year-ago quarter&#39;s figure of $9.9 million.
<h2>KB Home&#39;s Price Performance &amp; Valuation</h2>
KBH&#39;s stock has exhibited an upward movement in the past six months.&nbsp;The stock has gained 27.5%, outperforming the Zacks Building Products - Home Builders industry&#39;s rise of 16.4% in the same time frame.
The company has also outperformed its peer companies like Meritage Homes Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mth#NYSE">MTH</a>) (up 21.6% in the past six months) and Taylor Morrison Home Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmhc#NYSE">TMHC</a>) (up 16%).
<h2>6-Month Price Performance of KBH Stock</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2d/78791.jpg?v=1075297864" />
Image Source: Zacks Investment Research
Technical indicators suggest continued strong performance for KBH. Notably, the 50-day SMA continues to read higher than the 200-day SMA, signaling the bullish trend.
<h2>KBH Stock Trades Above 50 and 200-Day Moving Average</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/55/78793.jpg?v=505003855" />
Image Source: Zacks Investment Research
KBH stock is trading at a discount compared with the industry and slightly higher than its median. Despite the company&#39;s shares&#39; outperformance compared to its industry, KBH&#39;s current valuation is still considered undervalued. This might imply that the market has not yet fully recognized or priced in the company&#39;s potential growth prospects or earnings potential. The company is also trading currently at a discount compared to the industry&#39;s big shots like PulteGroup, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phm#NYSE">PHM</a>).
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/78792.jpg?v=689735686" />
Image Source: Zacks Investment Research
<h2>How to Play KB Home Stock?</h2>
Investors may want to hold KB Home stock due to its resilience in a challenging housing market, driven by strategic pricing and effective inventory management. Despite industry headwinds like expensive mortgages and slowing demand, KB Home has maintained strong financial performance through a focus on affordability and margin optimization. The company&#39;s BTO model has contributed to positive inventory dynamics, supporting confidence in their margin guidance for the second half of 2024.
While the recent Federal Reserve rate cut to 4.75%-5% may provide some market relief, its full impact on homebuilding remains uncertain, as mortgage rates may have already factored in the anticipated cut. Additionally, rising land costs, competition from the resale market, and supply chain disruptions pose challenges to the company&#39;s growth potential.
Though KB Home&#39;s stock has shown strength with a solid 50-day moving average and discounted valuation, a lack of upward estimate revisions in the past two months signals limited near-term upside. Investors might consider holding the stock while waiting for more favorable market conditions and further clarity on KB Home&#39;s long-term performance.
KB Home&#39;s operational resilience and strategic focus in a difficult environment make it a stock worth holding, although potential investors may opt for caution until clearer signals of stability emerge in both the company&#39;s performance and broader market trends.
<a href="https://www.zacks.com/stock/news/2339964/should-you-buy-sell-or-hold-kb-home-before-q3-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2339964">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Guidance

Technicals

Federal Reserve

TMHC

Should You Buy, Sell, or Hold KB Home Before Q3 Earnings?

<a href="https://www.benzinga.com/personal-finance/24/03/37464513/older-and-wiser-now-means-being-richer-baby-boomers-own-72-of-nations-wealth-but-gen-x-and-the-y">Baby Boomers</a> between ages 60 and 78 control a massive $76 trillion in wealth. This makes them the wealthiest retiring generation in history but they aren't parting with their money as quickly as many predicted.&nbsp;
Economists are wondering why these retirees are holding onto their fortunes instead of spending them like earlier generations did.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>
A recent episode of The Economist podcast, "The Intelligence," explores this unexpected trend. Senior economics writer Colin Williams notes that the big mystery isn't why boomers are being thrifty but spending so little overall. This shift impacts everything from the housing market to how younger generations think about their financial future.
So, what's behind this conservative approach? A few factors seem to be at play.
First, COVID has left a lasting mark. Williams points out that many boomers adopted what he calls "hermit-like habits" during the pandemic and these tendencies have stuck around even after restrictions were lifted. It's almost as if they're building wealth by accident without trying to.
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
Second, boomers are living longer, which raises financial concerns. A report from Corebridge Financial found that while 54% of Americans expect to live to 100, only 27% believe their savings will last that long. Boomers are eyeing a long retirement and <a href="https://www.benzinga.com/personal-finance/24/07/39780937/survey-reveals-67-of-55-year-olds-are-severely-underprepared-and-terrified-they-will-outlive-the">don't want to outlive their money</a>.
Then, there's the question of legacy. Many boomers feel a sense of duty to leave something behind for their children and grandchildren. "There's a lot of competing demands for their money," says Williams. He adds that boomers are "pretty stingy" with their wealth, which will not change anytime soon.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
The economic ripples from this trend are wide-ranging, <a href="https://www.benzinga.com/markets/24/09/40904058/investment-opportunities-are-popping-up-in-new-markets-as-baby-boomers-look-beyond-florida-for-retir">especially in the housing market.</a> Boomers stay put and this "aging in place" contributes to the housing shortage. A Redfin study shows the U.S. is short by four to seven million homes and three-quarters of homeowners over 60 plan to stay in their homes. This only adds pressure for younger buyers.
For those in Gen Z or millennials lucky enough to buy a home, it's not exactly what their parents had. Boomers own 28% of large homes with three or more bedrooms, while only 0.3% of Gen Z families can say the same.
See Also: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.
And what about the much-hyped Great Wealth Transfer? Cerulli Associates estimates that $53 trillion will pass down from boomers in the next decade. However, much of that wealth is concentrated in high-net-worth households. Plus, longer life spans and rising long-term care costs could eat into those inheritances, leaving less than younger generations hoped.
In the meantime, millennials and Gen Z are left to rethink their financial strategies, facing a future in which they may not receive the <a href="https://www.benzinga.com/general/24/03/37514748/boomers-are-expected-to-pass-90-trillion-in-assets-onto-millennials-leaving-them-to-become-the-riche">windfall they once anticipated.</a>
Read Next:
<ul>
<li>Don&#8217;t miss the real AI boom &#8211;<a href="https://www.benzinga.com/money/fundrise-innovation-fund"> here&#8217;s how to use just $10 to invest in high growth private tech companies.</a></li>
<li><a href="https://www.benzinga.com/money/charlie-munger-100k">Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</a></li>
</ul>

Personal Finance

Baby Boomers Are The 'Richest Generation Ever' But Being 'Pretty Stingy' With Their Money – And Younger Generations Are Feeling The Squeeze

WIIM

UXIN

Uxin shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Morgan Stanley analyst Patrick Wood maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight and maintains $45 price target.

TNDM

Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target

Morgan Stanley analyst Ryan Kenny maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Underweight and raises the price target from $61 to $67.

Morgan Stanley Maintains Underweight on Moelis, Raises Price Target to $67

Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company&#8217;s diabetes and weight-loss drugs, including <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39736330/bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us" rel="noreferrer noopener">Ozempic and Wegovy</a>.
The United States Senate Committee on Health, Education, Labor, and Pensions (HELP) <a target="_blank" href="https://www.help.senate.gov/hearings/why-is-novo-nordisk-charging-americans-with-diabetes-and-obesity-outrageously-high-prices-for-ozempic-and-wegovy" rel="noreferrer noopener">hearing</a> is scheduled for Tuesday, September 24th.
Leading the charge is Senator Bernie Sanders, chair of the Senate committee, who has been outspoken about the high cost of these medicines.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-" rel="noreferrer noopener">Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices</a>.
The President of the United States,&nbsp;Joe Biden,&nbsp;and&nbsp;Sen. Bernie Sanders,&nbsp;the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39600377/joe-biden-suggests-novo-nordisk-eli-lilly-to-lower-prices-for-its-popular-obesity-drugs" rel="noreferrer noopener">drugs in the U.S</a>.
Bernie Sanders <a target="_blank" href="https://www.sanders.senate.gov/in-the-news/novo-nordisk-is-ripping-off-the-american-people-bernie-sanders-says-of-ozempic-and-wegovy-costs/" rel="noreferrer noopener">said</a> the first question he would ask Novo Nordisk&#8217;s CEO at a Senate committee hearing is why the drugmaker charges up to 10 or 15 times more for&nbsp;Ozempic and Wegovy in the U.S. than other countries.
&#8220;This is absurd,&#8221; Sanders said in an interview late Tuesday. &#8220;It is clear that Novo Nordisk is ripping off the American people.&#8221;
Novo Nordisk is expected to defend the current prices, pointing to how most patients are covered by insurance and blaming pharmacy benefit managers for inflating drug prices through rebates.
Jørgensen is likely to highlight the extensive development costs of these drugs, which the company says exceeded $10 billion over three decades.&nbsp;&nbsp;
Novo Nordisk has invested over $30 billion in expanding its manufacturing capacity since early last year.
However, a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-23/ozempic-wegovy-sales-will-cover-68-billion-in-r-d-for-novo-nordisk" rel="noreferrer noopener">analysis</a> shows that Ozempic and Wegovy&#8217;s enormous sales, which are set to surpass $65 billion by the end of this year, undermine the company&#8217;s justification for the high prices.
After accounting for inflation, that figure would surpass the $68 billion Novo had invested in all research and development since the mid-1990s when the company began focusing on this class of drugs.
According to some analysts,&nbsp;Novo Nordisk&#8217;s blockbuster diabetes drug&nbsp;Ozempic&nbsp;and several other well-known medications might be included in Medicare&#8217;s negotiated <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug prices</a>.
Price Action: NVO stock is down 3.10% at $123.56 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40985825/tesla-and-chinese-ev-startups-outpace-toyota-volkswagen-in-critical-software-race-report" target="_blank" rel="noreferrer noopener">Tesla And Chinese EV Startups Outpace Toyota, Volkswagen In Critical Software Race: Report</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Legal

General

Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday

Macro Economic Events

Politics

Economics

Boeing's DC Office Cuts Political Donations, Lobbying

Treasure Global shares are trading higher after the company announced it entered into a partnership agreement with Credilab.

DA Davidson analyst Gil Luria downgraded the rating on Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to Neutral from Buy while maintaining a <a target="_blank" href="https://www.benzinga.com/quote/MSFT/analyst-ratings" rel="noreferrer noopener">price target of $475</a>.
Luria noted competition has essentially caught up with Microsoft on the AI front, which reduces the justification for the current premium valuation.
The analyst now ranked Microsoft fourth within the Magnificient Six. The stock increased 92% since his January 2023 initiation, compared to 49% for the S&amp;P500.
Luria noted that Microsoft has accelerated growth and extended margins over the last few quarters as the first to embrace and commercialize generative AI. Through an early investment in OpenAI and the ability to quickly deploy capabilities within Azure and GitHub, it took a significant lead over Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Service and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud, which translated to superior results over the prior 4-6 quarters.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19.png" alt="" class="wp-image-561547" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23123947/newplot-19-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The analyst noted that Microsoft&#8217;s lead is now diminished in both the cloud and code generation businesses, making it difficult for Microsoft to continue to outperform.
Luria said AWS is already adding nearly as much cloud business as Azure after a few quarters of Microsoft adding more business. Google Cloud Platform&#8217;s expansion has also seen its business accelerate to comparable growth rates as Azure prior quarter.
The analyst&#8217;s new proprietary hyperscaler semiconductor analysis indicates AWS and GCP are far ahead in deploying their silicon into their data centers, giving them a significant advantage over Azure in the future.
While Microsoft has discussed its Maia chips, it is years behind Amazon and Google and seems to be using them only to run Azure OpenAI Services workloads, he flagged. Luria noted this means Microsoft has been escalating an arms race it may not be able to prevail. He said this makes Microsoft beholden to Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which means it will continue to shift wealth from its shareholders to Nvidia shareholders.
After significant margin expansion last year, Microsoft is now guiding for a decline in operating margins to pay for the data center capex, increasing from 12% to 21% of revenue, Luria emphasized. This is a higher rate of increase than Amazon and Google due to Microsoft&#8217;s greater reliance on Nvidia.
The analyst said that Microsoft overinvests at these rates yearly, diminishing margins by at least 100 bps cumulatively. To offset the margin drag, Microsoft would need to lay off ~10,000 employees for every year of over-investment.
While Nvidia and others have pointed to a strong ROI for hyperscalers such as Azure, Luria flagged that these returns may only last for a while.
The analyst noted Azure&#8217;s growth may be boosted by self-funded revenue, such as from OpenAI.
Luria noted Microsoft has also lost much of the lead for GitHub Copilot. Not only have Amazon and Gitlab mostly caught up to GitHub Copilot&#8217;s capabilities, he said Cursor has become the new standard.
Luria projected fiscal first-quarter 2025 revenue of $64.2 billion and EPS of $2.96.
Price Action: MSFT stock is down 0.50% at $433.10 at last check Monday.
Photo via Shutterstock

Analyst Color

Downgrades

Tech

AMZN

GOOG

GOOGL

MSFT

NVDA

Microsoft's AI Lead Shrinks: Analyst Downgrades Stock As Amazon And Google Close The Gap

Morgan Stanley analyst Ryan Kenny maintains Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) with a Overweight and raises the price target from $56 to $60.

Morgan Stanley Maintains Overweight on Lazard, Raises Price Target to $60

<a href="https://www.snapone.com/press-room/snap-one-extends-partnership-with-sonos-to-australia-and-new-zealand-through-adi-distribution">https://www.snapone.com/press-room/snap-one-extends-partnership-with-sonos-to-australia-and-new-zealand-through-adi-distribution</a>
<h4> Snap One Extends Partnership with Sonos to Australia and New Zealand Through ADI Distribution</h4>
Building upon the success of its United States partnership, <a href="https://www.snapone.com/">Snap One</a>, now part of ADI, has announced that it will now serve as a distributor of the Sonos smart home sound system in Australia and New Zealand, creating a major new growth opportunity for integrator partners in the region.&nbsp;
&#x200D;
According to Snap One APAC Vice President and General Manager Adam Merlino, the entire Sonos product line is now available for pre-order on the Snap One ecommerce platform for delivery beginning on September 16, 2024.
&#x200D;
"The combined strength of Snap One and ADI has given us the opportunity to deliver more products and services, as well as more expertise and support to all of our partners," Merlino said today. "Our collaboration with Sonos, specifically, represents a significant opportunity for our integrator partners by providing high-quality audio solutions within smart home ecosystems or as a stand-alone solution."
&#x200D;
"Sonos is renowned for their wireless audio technology that enhances both residential and commercial environments with superior sound experiences. This partnership not only broadens the availability of Sonos products in Australia and New Zealand but also strengthens the 'Connects with Control4' program, ensuring seamless integration with Control4's Smart Home OS," he added.
&#x200D;
Additionally, the native compatibility with Integra AV receivers, cinema systems, and high-fidelity speaker options from Triad and Episode, ensures that customers receive a comprehensive and premium audio solution tailored to their needs.
&#x200D;
According to Sonos Country Director Rennie Addabbo, "We are thrilled to expand our partnership with ADI and Snap One to Australia and New Zealand. This collaboration ensures that our cutting-edge audio solutions are readily available to integrator partners in the region and reinforces our presence in the market as an additional distributor in the professional category, underscoring the growth potential for integrated solutions while complementing our existing distribution channels."&nbsp;
&#x200D;
Sonos will be featured at Snap One's upcoming APAC Partner Conference being held at the Novotel Sunshine Coast Resort from Wednesday 25th to 27th of September.&nbsp;
&#x200D;
For more information, see <a href="https://www.snapone.com/">here</a>. For hi-resolution images, see <a href="https://drive.google.com/drive/folders/1T-uKykMfWOdkySnYfbyh-oxRi1sIUElA?usp=sharing">here</a>.

SONO

Snap One Extends Partnership With Sonos To Australia And New Zealand Through ADI Distribution

Morgan Stanley analyst Manan Gosalia maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Equal-Weight and raises the price target from $146 to $163.

Morgan Stanley Maintains Equal-Weight on Houlihan Lokey, Raises Price Target to $163

VivoPower International (VVPR) has released an update. VivoPower International PLC has announced that its electric vehicle subsidiary, Tembo e-LV B...

VivoPower Announces Tembo's Merger Extension

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While investing in the best&nbsp;<a href="https://investorplace.com/stock-types/blue-chip-stocks/" target="_blank">blue chip stocks</a>&nbsp;to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10.



Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It&rsquo;s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right?



And these lower-priced stocks still can outperform the market. While the risks are higher, the rewards can be substantial, offering a tempting opportunity for investors willing to take on some level of risk.



I always suggest using the Portfolio Grader to help find the best stocks under $10. In fact, using a stock screening tool is essential in an exercise such as this.



Why? Because there are over&nbsp;<a href="https://money.usnews.com/investing/stocks/search?price-min=0&amp;price-max=10" target="_blank">2,100 stocks</a>&nbsp;on the market today are&nbsp;priced at $10 or less. No one can identify all of the best-performing stocks &ndash; or those that have the potential to perform &ndash; without using a screener like the Portfolio Grader to narrow the field.



The Portfolio Grader evaluates stocks based on various measurements, including earnings performance, growth, analyst sentiment, and momentum. The stocks under $10 on this list all score well enough to get at least a &ldquo;B&rdquo; rating in the Portfolio Grader tool.



<h2>Faraday Future Intelligent Electric (FFIE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/ffie1600-1-300x169.png" alt="Person holding cellphone with logo of electric vehicle company Faraday Future Inc. (FFIE) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Faraday Future Intelligent Electric (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) designs, manufactures and sells electric vehicles and related products. The California company operates in the United States and China.



The company has gotten into some hot water with Nasdaq and its listing requirements because the stock is less than $1 &ndash; it has until Aug. 31 to get the stock price up &ndash; and for not always promptly filing financial reports. 



Those are red flags for sure, so already you know FFIE stock is a speculative play.



Although revenue in 2023 was only $800,000, it was the company&rsquo;s first year of revenue, as it&rsquo;s still very much a startup. Faraday delivered its first-ever vehicles in the third quarter of the year.



However, Faraday also has some interesting things in the works, as outlined in its <a href="https://investors.ff.com/news-releases/news-release-details/faraday-future-hosts-investor-community-day-and-highlights">July 20 Investor Day event</a>. Highlights included a look at the All-Ability aiHypercar, its user ecosystem, and the company&rsquo;s Auto Industry Bridge strategy.



The company raised the idea of launching a second, lower-priced automotive brand. &ldquo;A second brand could strike in the mass market with volume production, bringing everyone the &lsquo;AI car of the future&rsquo; and the &lsquo;AI car of the people&rsquo;. 



We are preparing to launch the Bridge and second brand strategies in a future event where we will share more details and our progress. We are hopeful to set sail together in the blue ocean market with potential partners,&rdquo;&nbsp;founder YT Jia said.



The company scheduled a July 31 shareholder vote that includes a proposal for a 1-for-40 reverse stock split to maintain its Nasdaq compliance. For now, FFIE stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an up-and-coming technology company that is using artificial intelligence and machine learning to create products that recognize and respond to verbal prompts.



SoundHound&rsquo;s platform is used by restaurants to <a href="https://investors.soundhound.com/news-releases/news-release-details/beef-o-bradys-rolls-out-soundhounds-advanced-voice-ai-ordering">automate food ordering</a>, reducing employee costs. Through its Dynamic Interaction platform, customers can verbally place complicated orders at a kiosk and pay without the intervention of an employee.



Another interesting use of SoundHound&rsquo;s platform is its employee training. Inexperienced workers can use SoundHound to ask questions about a process and SoundHound&rsquo;s AI will answer intelligently and walk the employee through the proper steps.



SoundHound also has a product that has a <a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-chat-ai-launches-peugeot-opel-and-vauxhall-vehicles">Chat AI product</a> &ndash; integrated with ChatGPT &ndash; that can manage navigation, advise about the weather or tell stories to bored children in the back seat.



I also like that SoundHound is shoring up its financial position. The company <a href="https://finance.yahoo.com/news/soundhound-ai-announces-early-debt-130000956.html">announced</a> that it reached an agreement with lenders to repay $100 million in outstanding debt. Once that&rsquo;s done, SoundHound will have zero debt and a cash balance of $180 million.



<a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-ai-reports-73-q1-revenue-growth-116-million-first">Revenue in the first quarter</a>&nbsp;was $11.6 million, up 73% from a year ago. And with a subscription and booking backlog of $682 million, up 80% from just a year ago, I think SoundHound will start turning a profit soon.



SOUN stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) is an Australian oncology company that&rsquo;s developing therapies for brain, liver and renal cancers.



The company&rsquo;s lead program is paxalisib, which is currently in Phase 3 trials as a treatment for glioblastoma, which is an aggressive form of brain cancer. Paxalisib is also in Phase 2 trials as a treatment for childhood brain cancers, brain metastases, and non-Hodgkin&rsquo;s lymphoma.



The stock had massive gains this month when it announced <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">positive results</a> for paxalisib&rsquo;s glioblastoma trial. The company reported that patients who received paxalisib had a median overall survival period of 14.77 months, compared to 13.84 months for patients who did not receive the drug.



In a prespecified secondary analysis, the survival period for paxalisib patients was 15.54 months compared to 11.89 months for patients who did not take the drug.



Investing in biotech and pharma stocks can be very challenging because there&rsquo;s a lot of research &ndash; and a lot of expense &ndash; before a drug can even go to regulators for possible approval. But Kazia&rsquo;s work appears to be promising, and that&rsquo;s driving the momentum of KZIA stock right now.



Kazia stock is up 40% over the last month, and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Koss (KOSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/koss1600-300x169.png" alt="Koss Porta Pro Wireless headphones on a round case like on your head on a white background with reflection"><div>Source: PhotOleh / Shutterstock.com</div></div>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) is a manufacturer of headphones and accessories such as earbuds, electrostatic headphones and audio products for health care and education.



The company has been around for more than 60 years and came to renewed prominence in recent years as a popular meme stock. The meme factor makes Koss a volatile stock &ndash; shares jumped <a href="https://investorplace.com/2024/07/koss-stock-alert-koss-surges-90-on-renewed-meme-interest/">90% earlier this month</a> on speculative short-seller interest.



Earnings for the company&rsquo;s fiscal third quarter (ending March 31) showed weakening performance. Sales of $2.6 million was down from $3.3 million in the same quarter a year ago. Profits of $841,000 were down from $1.3 million on a year-over-year basis.



Koss is purely a meme stock play and should be treated with a lot of caution. If the stock jumps again &ndash; and odds are that it will &ndash; it would be wise to take profits at the peak.



KOSS stock is up 171% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>VivoPower International (VVPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charging-black-neon-1600-300x169.jpg" alt="Electric car backlit by cyan blue neon light next to EV charger with cyan blue light and lightning bolt symbol, all against a black background. ev stocks to buy"><div>Source: shutterstock.com/JLStock</div></div>VivoPower International (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) is an international battery technology and electric vehicle services company headquartered in the U.K. The company also operates in Australia, Canada, the Netherlands, the Philippines, the UAE and the U.S.



The company is preparing for a <a href="https://finance.yahoo.com/news/vivopower-announces-binding-heads-agreement-151900389.html">merger of its subsidiary</a>, Tembo E-LV, with Cactus Acquisition Corp. 1 Limited (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctsw-stock-quote/">CCTSW</a>), a special purpose acquisition company in preparation for taking Tembo public. Tembo, which is an electric vehicle services company in the Netherlands. 



Following the merger, the new Tembo Group expects to be publicly traded on the Nasdaq exchange. The new company would have a valuation of $838 million, with VivoPower shareholders receiving 20% of the company.



Thus, VVPR stock is an interesting bet on EVs with heavy European exposure. VivoPower stock is up 37% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Soligenix (SNGX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/sngx1600-300x169.png" alt="Soligenix is a leading biopharmaceutical firm developing drugs for rare diseases. It's renowned for solutions in oncology biodefense fields. SNGX stock"><div>Source: MacroEcon / Shutterstock.com</div></div>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) is a U.S. biopharmaceutical company that is working on a variety of products. It currently has several drug candidates in advanced stages of trials, including a treatment for early-stage cutaneous T-cell lymphoma in Phase 3 testing.



Soligenix has other Phase 2 tests underway for psoriasis, oral mucositis, and pediatric Crohn&rsquo;s disease.



But it&rsquo;s the early-stage cutaneous T-cell lymphoma trial that has investors excited. The stock jumped nearly 300% earlier this month &ndash; before giving some of those gains back &ndash; following a study testing HyBryte as a treatment). 



Six patients are enrolled in the yearlong study, with four of them completing at least 12 weeks of treatment. Of those, Soligenix says three patients already achieved treatment success, which is a 50% improvement in their cumulative mCAILS score compared to baseline. The fourth patient also saw improvement, the company said.



While this is a positive development, it&rsquo;s important to recognize that HyBryte is still a long way from making it to regulatory approval. But as a speculative play, SNGX stock has potential.



The stock is up 48% in the last month and has a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>First Foundation (FFWM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/piggy-bank-grad-300x169.jpg" alt="A pink piggy bank wearing a grad cap sits on a wooden table in front of a chalkboard."><div>Source: Shutterstock</div></div>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) is a regional bank that&rsquo;s headquartered in Dallas, but has offices in California, Florida, Hawaii, Nevada and Texas.



The bank has $13.6 billion in assets as well as $10.1 billion of loans, deposits of $10.6 billion and stockholder equity of $929 million.



It also just completed an <a href="https://investor.ff-inc.com/news/news-details/2024/First-Foundation-Inc.-Closes-228-Million-Equity-Investment-Anchored-by-Fortress-Investment-Group-Canyon-Partners-Strategic-Value-Bank-Partners-and-North-Reef-Capital/default.aspx">investment deal</a> with several investment firms, including Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners and North Reef Capital that injected $228 million into the company. First Foundation issued 11.3 million shares of stock valued at $4.10 each as part of the transaction.



The company is reporting second-quarter earnings on July 25, with <a href="https://investorplace.com/2024/07/why-is-first-foundation-ffwm-stock-down-27-today/">analysts expecting</a> flat adjusted earnings per share as well as revenue of $54.48 million. A year ago in the second quarter, FFWM saw $61.1 million in revenue and earnings of 7 cents per share.



Regional banking stocks have been challenging investments for the last few quarters, but FFWM appears to be on an upswing. The stock is up 25% in the last month and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/07/7-top-stocks-under-10-july-2024-edition/">7 Top Stocks Under $10: July 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Top Stocks Under $10: July 2024 Edition

VivoPower International (VVPR) has released an update. VivoPower International's subsidiary Tembo E-LV has entered into a definitive Business Combi...

VivoPower Subsidiary Tembo Strikes $904M Merger Deal

VivoPower International (VVPR) has released an update. VivoPower International PLC reported a 22% decline in annual revenue to $11.8 million for FY...

VivoPower Shifts Focus, Bolsters EV Business

VivoPower reports FY prelim revenue of $11.8M

VivoPower International (VVPR) has released an update. VivoPower International plc has entered into a business combination agreement with Cactus Ac...

VivoPower Announces Strategic Business Merger

VivoPower International (VVPR) has released an update. VivoPower International PLC has announced a preliminary agreement with Sansure Biotech Inc t...

VivoPower Partners for Mpox Test Distribution

VivoPower, Future Automotive Solutions to merge in all-stock deal

VivoPower International (VVPR) has released an update. VivoPower International PLC has announced plans to merge with the hydrogen technology compan...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Vivopower Intl

Vivopower Intl (VVPR) Forecast

Vivopower Intl (NASDAQ:VVPR) Stock, Quote.Headers.trade-ideas